Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Furmonertinib in Stage IA/IB NSCLC
NCT05445310Phase 2Recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Aug 2022
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of furmonertinib in non-small cell lung cancer (NSCLC), sponsored by Peking Union Medical College Hospital. Primary endpoint: Disease-free survival rate at 3 years. Started Aug 2022; status: recruiting.
02
Drugs
furmonertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05445310.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05445310.